Biotecher ImmunoLogik Syncs with aescuvest to Back Anti-HIV Drug, Nears Initial Funding Goal

December 19, 2017 @ 9:23 am By Erin Hobey |

The ImmunoLogik GmbH and the University of Erlangen-Nuremberg HIV research team have synced with aescuvest to raise funding for an innovative new drug. To date, the biotech company has raised more than €77,940, or more than 75% of its initial €100,000 goal. ImmunoLogik GmbH, a biotechnology company… Read More

Twitter
Facebook
LinkedIn
Pinterest
Reddit
HackerNews
Telegram
Weibo
Email
Print
Subscribe

Read more in: Investment Platforms and Marketplaces | Tagged biotech, holger dunker, targentas, ulrich schubert